In the third-line treatment of GC, the ORR of pembrolizumab in the treatment of PD-L1–positive GC (CPS ≥1) patients was 15.5% (45), and, based on this study, the pembrolizumab was approved in the treatment of PD-L1–positive advanced GC by FDA. Here, CD274 is linked to gastric cancer.